INZY Inozyme Pharma
- 4.610
- +0.200+4.54%
Inozyme Pharma News
RMBS, SANM and WGS Are Among After Hour Movers
12 Health Care Stocks Moving In Monday's After-Market Session
GainersGeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cas
Inozyme Pharma Is Maintained at Buy by B of A Securities
Inozyme Pharma Is Maintained at Buy by B of A Securities
B of A Securities Maintains Buy on Inozyme Pharma, Lowers Price Target to $14
B of A Securities analyst Tazeen Ahmad maintains Inozyme Pharma with a Buy and lowers the price target from $16 to $14.
Express News | Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Inozyme Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 298.61% Needham → $23 Reiterates Buy → Buy 03/13/2024 177.3% HC Wainwright & Co. $16 → $16 Main
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
Inozyme Pharma Announces Positive Topline Data From Ongoing Phase 1/2 Trials of INZ-701 in Adults...
Inozyme Pharma Announces Positive Topline Data From Ongoing Phase 1/2 Trials of INZ-701 in Adults With ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
Top 5 Health Care Stocks That May Plunge In March
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicat
ANGI, MLKN and KOD Are Among After Hour Movers
Express News | Inozyme Pharma Shares Are Trading Higher After the Company Announced That It Will Discuss Topline Data From Its Ongoing Phase 1/2 Trial of INZ-701 in Adults With ABCC6 Deficiency, and From All Cohorts of Its Ongoing Phase 1/2 Trial of INZ-701 in Adults Wi
Express News | Inozyme Pharma To Report Topline Data From Ongoing Phase 1/2 Trials Of INZ-701 In Adults With ABCC6 Deficiency And ENPP1 Deficiency On April 8, 2024
Inozyme Pharma: A Promising Buy Amid Anticipated Clinical Breakthroughs and Financial Stability
Inozyme Pharma Is Maintained at Buy by HC Wainwright & Co.
Inozyme Pharma Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Inozyme Pharma, Maintains $16 Price Target
Analysis
Price Target
No Data
